Resyca®, a leader in soft mist-based drug delivery with its next-generation Soft Mist Inhalers and Soft Nasal Sprays, announced the appointment of Deborah Jones, Ph.D., as Chief Executive Officer, effective immediately. She succeeds Remko Beimers, who is stepping down. The shareholders thank Mr Beimers for his leadership and significant contributions to the company’s growth and transformation.
As CEO, Dr Jones will lead Resyca’s next phase of growth, expanding strategic collaborations with global pharmaceutical and biotech partners and advancing its soft mist inhaler and nasal spray platforms. Her focus will be on enabling more efficient, patient-friendly drug delivery and strengthening Resyca’s position as a trusted partner in integrated drug–device combination development.
Dr Jones brings more than 20 years of executive leadership experience driving commercial growth in life sciences technology companies. She has guided organisations through international expansion, strategic partnerships, and technology platform scaling to deliver sustained revenue growth. She joins Resyca from Proveris Scientific, where she led commercial strategy across EMEA and India and played a pivotal role in advancing the global adoption of aerosol and spray characterisation technologies. She is widely recognised for her expertise in understanding the complexities in inhalation and nasal drug development.
“I am excited to join Resyca at such a pivotal time in the evolution of inhaled and nasal drug delivery,” said Dr Jones. “Soft mist technologies represent a significant step forward in optimising drug deposition, improving ease of use, and enhancing dose consistency. With Resyca’s technologies, we can improve adherence, therapeutic effectiveness, and ultimately patient outcomes.”
About Resyca
Resyca® is redefining drug delivery with its next‑generation Soft Mist Inhalers and Soft Nasal Sprays. Founded in 2020 as a joint venture between Medspray and Bespak, Resyca develops advanced, proprietary delivery platforms that integrate Medspray’s micro‑nozzle technology.
With Resyca’s delivery devices, pharmaceutical partners can clearly differentiate their therapies through highly efficient pulmonary delivery and precise nasal administration—making Resyca’s platforms an excellent fit for a broad spectrum of drug–device combination products.
To further accelerate development and commercialisation, Resyca supports pharmaceutical partners with a comprehensive suite of services spanning early‑stage development through to full commercial launch.
